Affymax, Inc. (AFFY)
-OTC Markets 1.07 0.00(0.00%) Jun 19, 3:59PM EDT
| Prev Close: | 1.07 |
|---|
| Open: | 1.08 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | 1.8 |
|---|
| Next Earnings Date: | 6-Aug-13 |
|---|
| Day's Range: | 1.02 - 1.08 |
|---|
| 52wk Range: | 0.78 - 27.74 |
|---|
| Volume: | 640,608 |
|---|
| Avg Vol (3m): | 7,183,050 |
|---|
| Market Cap: | 40.11M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -4.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Questcor Pop: Acquisition Trumps Competitionat Motley Fool(Wed, Jun 12)
- AFFYMAX INC FinancialsEDGAR Online Financials(Sat, Jun 8)
- CFO Moves: Affymax, State Street, Compuwareat The Wall Street Journal(Fri, Jun 7)
- AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive AgreEDGAR Online(Fri, Jun 7)
- Affymax Announces Update on Listing, Senior Leadership and Board ChangesBusiness Wire(Thu, Jun 6)
- The Nasdaq's 5 Most Hated Stocksat Motley Fool(Wed, Jun 5)
- [video] SAC Update, Nasdaq to Delist Affymaxat CNBC(Tue, Jun 4)
- Affymax Drops On Nasdaq Delisting And Criticismat Seeking Alpha(Tue, Jun 4)
- Monday’s movers: Zynga sinks on layoff planat MarketWatch(Mon, Jun 3)
- Ford Rides Canadian Truck Demand and 2 Other Hot Stocks to Watchat Wall St. Cheat Sheet(Mon, Jun 3)
- Largest option buying in equities so faroptionMONSTER(Mon, Jun 3)
- Stocks to Watch: Cracker Barrel, Synta Pharma, Affymaxat The Wall Street Journal(Mon, Jun 3)
- Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha(Mon, Jun 3)
- 5 Breakout Stocks Ready to Surge Higherat TheStreet(Fri, May 31)
- Final Trade: Your First Move for Monday, June 3at CNBC(Fri, May 31)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.25 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.79 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.41 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | -0.09 |
|---|
Business Summary
Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses.
View More